Introduction
Pulmonary complications occur in about 50% of hematopoietic stem cell transplant (HSCT) recipients. 1 There is an extensive differential diagnosis for pulmonary infiltrates after HSCT and a diagnosis by non-invasive testing is difficult. Diffuse alveolar hemorrhage (DAH), peri-engraftment respiratory distress syndrome and acute respiratory distress syndrome can all look similar on chest X-rays 2 and computed tomographies, 3 and this appearance is shared with heart failure, viral pneumonia and atypical bacterial pneumonia.
Fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) is thought to be the procedure of choice to evaluate pulmonary infiltrates in HSCT recipients. 4 In the past, diagnostic yields were seen in up to 74% with changes in management dictated in up to 41% of patients. [5] [6] [7] [8] [9] We hypothesized that additional treatments based on results from a bronchoscopy performed on post-HSCT patients in the last 10 years would not lead to a detectable prolongation of survival. Because prior studies included patients enrolled when transplant supportive care and empiric treatments were less sophisticated [10] [11] [12] [13] [14] and previous reports allowed any changes in management rather than focusing on the addition of new treatments after bronchoscopy revealed an unanticipated diagnosis, this might have diluted any survival benefit that could be retrospectively evaluated and not reflect current diagnostic yields. Our goals were to evaluate the yield and utility of FOB juxtaposed to the risk of complications.
Materials and methods
All in-patient HSCT patients who underwent bronchoscopy with or without transbronchial biopsy from January 1994 to December 2004 were identified by a review of computerized hospital records. For patients who underwent multiple bronchoscopies, each bronchoscopy was considered independently.
Transplant population and prophylactic anti-infectives Loyola University Medical Center performs approximately 130-160 HSCTs per year in in-patient or outpatient units. The in-patient unit has 13 beds in a closed unit and four beds with intensive care capabilities. The outpatient unit has 12 beds in the Cardinal Bernardin Cancer Center that is used for lower risk transplants and for follow-up in the first 100 days after discharge.
Anti-infective prophylactic regimens began from the day of transplant and continued until the immunosuppression was tapered off, generally after the first 100 days. Antifungal prophylaxis began the day after transplant and consisted of fluconazole for autologous transplants. Matched sibling transplants received fluconazole before engraftment and itraconazole suspension after discharge. Matched unrelated donors received prophylactic doses of amphotericin until engraftment and itraconazole after discharge. Herpes simplex virus (HSV) and cytomegalovirus (CMV) prophylaxis consisted of high-dose acyclovir until engraftment and then valacyclovir as an outpatient. Pneumocystis jiroveci pneumonia (PCP) prophylaxis consisted of double-strength bactrim twice daily on two consecutive days per week. The only prophylaxis that began before the day of transplant was norfloxacin; this was given to all patients receiving a myeloablativeconditioning regimen and continued until engraftment. Assuming no carbapenem allergy or life-threatening penicillin allergy, a neutropenic fever led to a switch from norfloxacin to imipenem as monotherapy.
Standard bronchoscopic technique
The decision to perform a bronchoscopy was at the discretion of the attending physician caring for the patient.
FOB was performed by a Pulmonary and Critical Care Medicine fellow and attending physician. The procedure was performed at the bedside in one of four intensive care unit-capable rooms in the bone marrow transplant unit. The bronchoscopist determined which lung segment(s) would be lavaged and/or biopsied. In general, the right middle lobe was lavaged if it was affected. Additional segments that were visibly affected may also have been lavaged. BAL fluid was submitted to microbiology for Gram stain and bacterial culture, mycology culture, acidfast staining and culture for mycobacteria, viral cultures, shell vial for CMV, and direct fluorescent antibody for Legionella sp and Pneumocystis sp. BAL fluid was submitted to cytopathology for visual review and transbronchial tissue was submitted to surgical pathology.
Diagnostic criteria
American Thoracic Society (ATS) guidelines 15 support a diagnosis if any of the following are recovered from BAL fluid: Pneumocystis, Toxoplasma, Strongyloides, Histoplasma, Mycobacterium, Influenza and respiratory syncytial virus. The recovery of non-tuberculous mycobacteria from BAL fluid was felt to be diagnostic at either the definite or probable levels based on criteria from the Centers for Disease Control and Prevention 16 in this immunosuppressed population with pulmonary infiltrates.
Although these guidelines considered the recovery of Aspergillus simply suggestive because of data at the time in non-transplant patients, 17 follow-up studies 18 and guidelines [19] [20] [21] in neutropenic patients suggest that recovery of Aspergillus on BAL has a low sensitivity but high specificity. We therefore considered any identified fungus at a level of more than a single colony as diagnostic but provide the proven, probable and possible categories according to international consensus guidelines. 21 CMV pneumonia was diagnosed with either a positive culture result from BAL fluid sample or identification of characteristic intranuclear inclusions in either BAL fluid or transbronchial biopsy tissue. Carmustine (BCNU) pneumonitis was diagnosed when other infectious etiologies had been excluded and transbronchial biopsy showed interstitial inflammation and atypical reactive pneumocytes typical of a drug reaction.
Bacterial pneumonia was diagnosed in patients when bacterial cultures from BAL fluid predominantly grew one or two bacteria -quantitative cultures were not consistently performed. A few colonies of Candida or other yeast were not diagnostic unless this was also isolated on blood or pleural fluid cultures or there was histologic evidence on transbronchial or lung biopsy.
DAH (e.g. hemorrhagic alveolitis) was diagnosed with a progressively bloodier return on BAL, bilateral pulmonary infiltrates on chest X-rays, no infectious pathogen detected in the BAL fluid and no evidence of cardiogenic pulmonary edema. Our laboratory does not routinely examine BAL fluid for hemosiderin-laden macrophages.
Definition of a change in management
A change in the clinical management of the patient was defined as any addition to the prebronchoscopy treatment regimen attributable to positive or negative results from the bronchoscopy or transbronchial biopsy.
Statistics
Kaplan-Meier survival analysis was calculated using the SPSS statistical package (Chicago, IL, USA). When a patient had more than one bronchoscopy, Kaplan-Meier analysis was performed using data from the first bronchoscopy to the date of death. The log rank comparison of groups (Mantel-Cox) was used to analyze survival of different subgroups after bronchoscopy.
Results
From January 1994 to December 2004, 1651 myeloablative HSCTs were performed at Loyola University Medical Center of which 67% were autologous and 33% were allogeneic. Among these transplants, the median age at the time of transplant was 47 years (1-80 years ) and the gender split was 47% male and 53% female. The five most common diseases that led to transplant in this time period were non-Hodgkin's lymphoma (25%), acute myelogenous leukemia (12%), breast cancer (12%), ovarian cancer (12%) and multiple myeloma (11%). The number of HSCT patients admitted to the hospital or treated for pneumonia while an in-patient was 190.
We reviewed all 101 bronchoscopies performed in this time period, of which complete records were available from 91 bronchoscopies in 78 patients (Table 1) . Table 2 delineates the results from the 45 (49%) bronchoscopies that yielded a diagnosis. The most common organism isolated from the BAL fluid was Aspergillus species although this was seen on only one transbronchial biopsy; hence, 11 patients would be categorized as probable Aspergillus infection and only one as proven. 21 The second most common isolate was split between CMV, Gramnegative bacteria and other viruses. All patients with CMV were found to be viremic when the peripheral blood was tested by hybrid capture assay (Digene Corporation, Gaithersburg, MD, USA) before the bronchoscopy was performed. The recovered Gram-negative bacteria included Pseudomonas [3] , Acinetobacter [1] , Escherichia coli [1] and Enterobacter [1] . The other viruses isolated were uniformly fatal and included Adenovirus [2] , HSV [1] , Influenza A [1] and Parainfluenza type III [2] . DAH was diagnosed after five bronchoscopies, but this led to the addition of steroids in only two instances as the other three patients had suffered hemoptysis and had already received methylprednisolone. Pneumocystis was isolated from one patient who was not compliant with his prophylactic medications.
Although four transbronchial biopsies returned a diagnosis (BCNU pneumonitis, Aspergillus, CMV, Gramnegative rod pneumonia), only one (5%) of 21 transbronchial biopsies performed provided a diagnosis when the BAL fluid analysis was negative. This occurred in a patient with suspected BCNU-induced pneumonitis who was treated with steroids after the specimen was reviewed by pathologist -this patient is alive 5.5 years after his autologous transplant for chemotherapy-sensitive relapsed Hodgkin's lymphoma.
Out of 30 patients intubated at the time of bronchoscopy, 13 (43%) were diagnostic but only six (20%) of those 30 lived more than 2 months after bronchoscopy. In contrast, out of the 61 patients who were not intubated at the time of bronchoscopy, 29 (48%) were diagnostic and 26 (43%) lived more than 2 months from the date of bronchoscopy. A diagnosis of ventilator-associated pneumonia was not possible because all patients had pulmonary infiltrates before, or at the time of the initiation of mechanical ventilation. 22 When treating the bronchoscopy as the unit of analysis, there were 91 cases, of which 12 were censored as they are still alive. The median survival was 35 days after bronchoscopy ( Figure 1 ) and among those 12 patients who underwent more than one bronchoscopy, the median survival was 53 days. The median survival after a bronchoscopy that did not yield a diagnosis was 46 days, and 29 days after a diagnostic one (P ¼ 0.165). The median survival after a bronchoscopy that yielded a diagnosis and that led to additional treatment was 31 and 24 days for those that did not lead to more treatment (P ¼ 0.546). When comparing survival of autograft and allograft recipients after bronchoscopy, the overall survival at 100 and 365 days was 50 and 33% in autograft recipients versus 25 and 17% in allogeneic recipients (P ¼ 0.04).
There were seven complications out of 91 bronchoscopies. Three patients were intubated after the transbronchial biopsy was performed after they became hypoxemic owing to bleeding from the biopsy site. One intubated patient with high peak airway pressures developed pneumomediastinum within 1 day of a BAL without transbronchial biopsy. Three additional patients bled after the transbronchial biopsy was performed, but all three episodes resolved with local treatment. We did not consider the requirement of mechanical ventilation within 24 h of bronchoscopy as a complication as this was difficult to attribute to the procedure rather than the continued progression of the pulmonary process.
Discussion
Out of 91 bronchoscopies reviewed in 190 in-patient HSCT recipients that were admitted or treated for pneumonia from January 1994 to December 2004, our review revealed a relatively high diagnostic yield of 49% but an overall survival of only 35 days. Furthermore, we were unable to detect any survival benefit from an addition to the treatment regimen after a positive result from analysis of the BAL fluid or the transbronchial biopsy.
In the largest study of bronchoscopy in non-human immunodeficiency virus immunocompromised patients with pulmonary infiltrates, Rano et al. 23 (27% HSCT recipients) described three variables that predicted mortality: increasing severity of illness, need for mechanical ventilation and delay in diagnosis. In our review, 20% of ventilated patients lived more than 60 days from bronchoscopy in comparison to 43% in non-intubated patientsthis supports other published reports that only autograft recipients intubated for uncomplicated lung injury 24 and allograft recipients intubated at the time of engraftment 25 should be expected to survive to hospital discharge. Rano et al. 23 showed that a delay greater than 5 days in the identification of the cause of the pulmonary infiltrates increased the risk of death threefold, but we found that survival was not statistically different after a diagnostic or non-diagnostic bronchoscopy; this difference may be accounted for by our focus on only HSCT patients. This suggests that other variables such as the extent or severity of graft-versus-host disease (GVHD), the forced expiratory volume in 1 s to forced vital capacity ratio, or cumulative steroid treatment may better predict patients more likely to die from an opportunistic pulmonary infection.
Diagnosis of pulmonary aspergillosis based on BAL samples is difficult because Aspergillus is seldom retrieved, theoretically owing to its vascular rather than alveolar location. We were more successful in isolating Aspergillus from 12 (13%) of 91 BAL fluid samples compared to one (5%) of 21 transbronchial biopsies. Autopsies performed on three of these patients with Aspergillus in their BAL fluid found widespread aspergillosis. It has been reported that the primary risk factors for fungal pulmonary disease include duration of neutropenia and GVHD. 26 The positive predictive value of recovery of Aspergillus in respiratory secretion in HSCT recipients is as high as 80-90%, and most isolates require treatment. 27 Prospective studies are needed to determine the benefit of antigen testing (e.g. galactomannan) of the serum 28, 29 and BAL fluid. 30 We suspect that because patients evaluated in our study were accrued during an era with improved prophylaxis against PCP, 12 Candida 10 and CMV 11, 13, 14 and an increase in the proportion of invasive fungal infections, 31 Aspergillus has become the predominant organism 8 compared to older studies. 5, 6, 9 Transbronchial biopsies in our series led to more complications than unique diagnoses. Six out of a total of seven bronchoscopy complications in our series were directly related to the transbronchial biopsy. The diagnostic yield of a transbronchial biopsy when the BAL is unrevealing was only 5% in this study. Our results are in agreement with the 12% yield reported by White et al.,
9 the largest series of transbronchial biopsies reported in post-HSCT patients. We now avoid transbronchial biopsies because of this high rate of complications combined with a low diagnostic yield. Table 3 compares our results to other studies published after 1990 in adult post-HSCT patients. Our yield, utility and incidence of major complications were comparable to other groups. The study by Glazer et al. 7 showed the highest yield, but this may be explained in part because they did not include any information on their prophylactic antiinfective regimen, they did not document what criteria were used to establish a diagnosis of bacterial pneumonia and they diagnosed idiopathic pneumonia syndrome from histologic features which are not standard. Soubani et al. 32 reported an unusually high yield from transbronchial biopsies, but this likely resulted from a retrospective review of only metastatic breast cancer patients who had received autografts conditioned with BCNU and cyclophosphamide, biasing the yield to drug toxicity or recurrent cancer. 33, 34 There are a number of limitations to our retrospective study. Selection bias must be acknowledged as only 101 bronchoscopies were performed out of 190 discharges where pneumonia was a treated diagnosis, skewing the patient group to in-patients who had pulmonary processes that were resistant to initial therapy yet still allowed our pulmonologists adequate time to perform a bronchoscopy. Non-diagnostic bronchoscopies.
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Cumulative survival Figure 1 Survival from bronchoscopy depending on diagnostic yieldKaplan-Meier survival analysis with a log rank comparison of groups (Mantel-Cox) to analyze survival of different subgroups after bronchoscopy. The median survival after a bronchoscopy that yielded a diagnosis and that led to additional treatment was 31 and 24 days for those that did not lead to more treatment (P ¼ 0.546). The median survival after a bronchoscopy that did not yield a diagnosis was 46 and 29 days after a diagnostic one (P ¼ 0.165). When a patient had more than one bronchoscopy, Kaplan-Meier analysis was performed using data from the first bronchoscopy to the date of death.
This does not represent the total number of pulmonary events as many patients were treated in clinic or at our infusion center. The 10-year period from which bronchoscopies were reviewed included different non-invasive testing techniques (bronchoscopies are now rarely performed if non-invasive testing reveals CMV viremia) and microbiologic pressures from a variety of prophylactic anti-virals and anti-fungals. Additional selection biases include incomplete records for 10 bronchoscopies, relatively small sample size and a disease distribution specific to a single center. Our distribution of malignant diseases is different from most transplant centers in the US in that it contains a larger percentage of Hodgkin's and non-Hodgkin's lymphoma allograft patients, slightly fewer with myelodysplastic syndrome, and more with chemotherapy-responsive metastatic ovarian cancer with less than 2 cm of residual disease at the time of transplant. 35 Although BAL fluid has been proven to identify patients with PCP as well as pulmonary reactivation of CMV, this is seldom needed with patients on effective PCP prophylaxis. CMV pneumonia is now a rare complication that is better detected by routine serum antigen assays; in our review, all patients tested were viremic at the time of bronchoscopy. In our population, the ability of a BAL to identify bacterial, fungal or other viral infections in patients who could still benefit from a change in therapy can be questioned. With complication rates ranging from 4 to 9% in the above trials and additions to treatment in only 20%, a randomized prospective trial could provide evidence that routine bronchoscopy will lead to a statistically prolonged survival when compared to empiric treatment without bronchoscopy. Empiric treatment mandates diagnostic uncertainty and risks potentially lethal side effects. Ideally, novel non-invasive methods will be developed to better diagnose lower respiratory tract pathologies.
In summary, we found an approximate 50% yield from a bronchoscopy, additional treatment given after only 20% of reviewed bronchoscopies and no survival benefit was retrospectively detectable after a bronchoscopy that yielded a diagnosis. The most common bacteria isolated was Pseudomonas that was often resistant to the patient's current antibiotics, suggesting that in lieu of a diagnostic procedure, changes to better cover resistant Gram-negative bacteria are reasonable. The complication rate can be reduced and the diagnostic yield preserved if a transbronchial biopsy is not performed.
